Related Experiment Videos
Antimicrobial postexposure prophylaxis for anthrax: adverse events and adherence.
Colin W Shepard1, Montse Soriano-Gabarro, Elizabeth R Zell
1Centers for Desease Control and Prevention , Atlanta, Georgia 30333, USA. cvc8@cdc.gov
Emerging Infectious Diseases
|October 25, 2002
Summary
Antimicrobial prophylaxis for anthrax exposure had common adverse events, but serious events were rare. Poor adherence (44%) was observed over 60 days, with variations across U.S. sites.
Area of Science:
- Public Health
- Infectious Disease Epidemiology
- Pharmacovigilance
Background:
- Anthrax (Bacillus anthracis) exposure necessitates postexposure prophylaxis (PEP).
- Understanding adverse events and adherence is crucial for effective PEP strategies.
- Previous PEP campaigns provide data on real-world outcomes.
Purpose of the Study:
- To evaluate adverse events and adherence during anthrax PEP.
- To identify factors influencing adherence to antimicrobial prophylaxis.
- To assess the safety and effectiveness of PEP protocols.
Main Methods:
- Data collected from six U.S. sites following Bacillus anthracis exposures.
- Evaluation of prophylaxis programs up to 60 days post-antimicrobial prophylaxis initiation.
- Analysis of reported adverse events and adherence rates.
Main Results:
- Adverse events were common with antimicrobial prophylaxis, but hospitalizations and serious adverse events were rare.
- Overall 60-day adherence was poor at 44%, with significant site-to-site variation (21%-64%).
- Highest adherence was observed in participants receiving additional antibiotics/vaccine, suggesting higher perceived risk.
Conclusions:
- Antimicrobial prophylaxis for anthrax is generally safe, with rare serious adverse events.
- Improving adherence to 60-day prophylaxis regimens is a critical public health challenge.
- Risk perception may significantly influence patient adherence to anthrax PEP.